Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Stimit is raising $29,634,446.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Michael Goldberg played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Stimit

STIMIT’s proprietary technology enables extended local delivery of cancer immunotherapy in the context of tumor resection, the standard of care for most patients with solid tumors. Concentrating and retaining the action of potent immunomodulators locally dramatically improves the efficacy and safety of these compounds relative to administration in solution, whether via intravenous or even intratumoral injection.

To learn more about Stimit, visit http://stimittx.com/

Contact:
Michael Goldberg, President and Chief Executive Officer
617-909-8181
https://www.linkedin.com/in/michael-goldberg-2b84175/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved